Scarica l'app Stockscreener
177.84
0.06%
-0.10
Pre-mercato:
181.70
3.86
+2.17%
Precedente Chiudi:
$177.94
Aprire:
$176.65
Volume 24 ore:
813.70K
Relative Volume:
0.65
Capitalizzazione di mercato:
$14.36B
Reddito:
$8.19B
Utile/perdita netta:
$758.19M
Rapporto P/E:
19.37
EPS:
9.18
Flusso di cassa netto:
$1.06B
1 W Prestazione:
+3.54%
1M Prestazione:
+6.85%
6M Prestazione:
-6.41%
1 anno Prestazione:
-44.78%
Intervallo 1D:
$172.90
$178.49
Intervallo di 1 settimana:
$169.99
$179.44
Portata 52W:
$125.10
$323.25
Icon Plc Stock (ICLR) Company Profile
Nome
Icon Plc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ICLR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
177.84 | 13.84B | 8.19B | 758.19M | 1.06B | 9.18 |
|
TMO
Thermo Fisher Scientific Inc
|
487.53 | 186.06B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
203.79 | 147.38B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
639.45 | 51.77B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
125.21 | 35.62B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
183.74 | 32.44B | 15.70B | 1.24B | 2.01B | 6.91 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-21 | Downgrade | Citigroup | Buy → Neutral |
| 2025-07-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-04-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-04-14 | Downgrade | TD Cowen | Buy → Hold |
| 2025-04-10 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-03-21 | Downgrade | Goldman | Buy → Neutral |
| 2025-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-10-14 | Iniziato | Redburn Atlantic | Neutral |
| 2024-09-18 | Iniziato | Leerink Partners | Outperform |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2023-12-15 | Iniziato | Truist | Buy |
| 2023-09-13 | Iniziato | TD Cowen | Outperform |
| 2023-01-17 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-01-13 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-11-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-09-07 | Iniziato | UBS | Buy |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-05-24 | Iniziato | Guggenheim | Buy |
| 2022-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-04-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2021-09-27 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-23 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-14 | Iniziato | Citigroup | Neutral |
| 2021-04-13 | Ripresa | BofA Securities | Neutral |
| 2021-04-01 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-03-08 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-03-03 | Iniziato | Barclays | Equal Weight |
| 2021-03-01 | Aggiornamento | UBS | Neutral → Buy |
| 2021-02-26 | Aggiornamento | Truist | Hold → Buy |
| 2020-07-24 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-03-02 | Iniziato | Deutsche Bank | Hold |
| 2020-01-27 | Downgrade | SunTrust | Buy → Hold |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Neutral |
| 2019-09-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-07-26 | Aggiornamento | UBS | Sell → Neutral |
| 2019-01-25 | Aggiornamento | Mizuho | Neutral → Buy |
| 2018-10-26 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-10-09 | Iniziato | UBS | Sell |
| 2018-04-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-15 | Reiterato | Mizuho | Neutral |
| 2018-01-19 | Iniziato | Evercore ISI | Outperform |
| 2017-10-27 | Reiterato | Barclays | Equal Weight |
| 2017-09-11 | Iniziato | BofA/Merrill | Buy |
| 2017-07-31 | Aggiornamento | SunTrust | Hold → Buy |
| 2017-07-27 | Reiterato | Mizuho | Neutral |
| 2017-06-29 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Icon Plc Borsa (ICLR) Ultime notizie
Healthcare Stocks to Watch: argenx, ICON, and Edwards Lifesciences with Long-Term Potential - AInvest
ICON plc to Participate at Upcoming Investor Conferences - PharmiWeb.com
ICON plc to Participate at Upcoming September 2025 Investor Conferences - BioSpace
ICON plc Announces Participation in September 2025 Investor Conferences - TipRanks
ICON plc Announces Participation in Upcoming Investor Conferences - AInvest
ICON’s SWOT analysis: stock outlook amid industry headwinds and opportunities - Investing.com
Icon (ICLR) Stock Price, News & Analysis - MarketBeat
ICON’s Interim Financials Prompt Fresh Questions About Operational Agility and Efficiency for ICLR Investors - Yahoo Finance
Does ICON’s (ICLR) Interim Update Reveal New Clues About Efficiency in Clinical Research Outsourcing? - simplywall.st
ICON plc Releases Interim Financial Statements for 2025 - The Globe and Mail
AstraZeneca and Icon Plc’s Study on ATTR Amyloidosis: Key Insights for Investors - TipRanks
ICON Properties Plc (Malawi) declared a final dividend of 0.15 MWK per share - AfricanFinancials
ICON plc (ICLR) Investor Outlook: Navigating a 23% Upside Potential Amidst Market Volatility - DirectorsTalk Interviews
Earnings call transcript: ICON plc beats Q2 2025 earnings expectations - Investing.com
Citi Downgrades Icon PLC(ICLR.US) to Hold Rating, Cuts Target Price to $200 - 富途牛牛
ICON plc Halts COVID Vaccine Study Due to BARDA Stop Work Notice - AInvest
Healthcare Sector Rebound: Is Now the Time to Buy High-Quality CROs Like ICON? - AInvest
ICON suspends COVID vaccine study after BARDA notice - MSN
Icon Plc (NASDAQ:ICLR) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Icon Suspends COVID Vaccine Study After BARDA Notice, Impacting H2 2025 Revenue - AInvest
ICON plc Halts COVID Vaccine Study Following BARDA Notice - MSN
Icon PLC Shares Jump 4.26% on $250M Volume as Analysts Target 25% Gains Despite 462nd Rank - AInvest
BARDA Stops ICON COVID Vaccine Study, Company Suspends New Enrollments - AInvest
ICON suspends COVID vaccine study after BARDA notice to sponsor - Seeking Alpha
ICON plc Provides Update on Vaccine Study - MarketScreener
ICON (ICLR) Fell Along with Broader CROs - Insider Monkey
ICON plc (ICLR) Fell due to Persistent Volatility in the Clinical Development Market - Insider Monkey
ICON plc (ICLR) stock fell due to persistent volatility in the clinical development market. - AInvest
Arkadios Wealth Advisors Purchases 6,666 Shares of Icon Plc (NASDAQ:ICLR) - Defense World
Fund Update: First Pacific Advisors, LP added 417,173 shares of ICON PLC ($ICLR) to their portfolio - Quiver Quantitative
ICON Plc’s Earnings Call: Balancing Achievements and Challenges - TipRanks
ICON plc: Initiation of Coverage- Capitalizing On Opportunities in China, A Critical Growth Market! - smartkarma.com
ICON Plc's Q2 Earnings Call: Balancing Growth and Challenges - AInvest
Deutsche Bank Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $210 - 富途牛牛
Leerink Partners Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $240 - 富途牛牛
ICON plc’s SWOT analysis: navigating challenges in CRO stock landscape By Investing.com - Investing.com India
ICON plc’s SWOT analysis: navigating challenges in CRO stock landscape - Investing.com
ICON's Intrinsic Value Estimated at $278, 33% Undervalued by Current Share Price - AInvest
Thermo Fisher, Baker Hughes And IQVIA Holdings Are Among Top 10 Large Cap Gainers Last Week (July 21-July 25): Are The Others In Your Portfolio? - Benzinga
Icon price target raised to $225 from $173 at Mizuho - TipRanks
ICON plc Q2 2025 Financial Results: Revenue Up 0.8%, Net Income Rises 30.7% - AInvest
UBS Raises Icon PLC Price Target to $240, Maintains 'Buy' Rating - AInvest
Icon PLC (ICLR) Sees Price Target Boost Amid Stable Booking Trends - AInvest
ICON plc Reports Strong Q2 2025 Financial Results - The Globe and Mail
ICON plc Expands Share Repurchase Program and Resumes COVID Vaccine Study - The Globe and Mail
ICON plcOrdinary Shares (Nasdaq:ICLR) Stock Quote - FinancialContent
Evercore Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $240 - 富途牛牛
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $209 to $240 - 富途牛牛
Icon PLC (ICLR) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Wins - GuruFocus
Icon PLC (ICLR) Q2 2025 Earnings Call Highlights: Navigating Cha - GuruFocus
Icon Plc Azioni (ICLR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.76%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):